Rifaximin 550 mg
Rifaximin 550mg — same gut-selective RNA polymerase inhibition mechanism as RIFATUF 400. The 550mg dose is the guideline-specified dose for hepatic encephalopathy prevention and treatment, where the slightly higher drug concentration achieves more complete suppression of ammonia-producing gut bacteria. See RIFATUF 400 for full mechanism detail.
Hepatic encephalopathy: prevention of recurrent overt HE in adults with liver cirrhosis (550mg twice daily — standard FDA/EMA approved regimen). This is the primary indication distinguishing RIFATUF 550 from RIFATUF 400. Also used in traveller's diarrhoea (off-label at higher dose) and SIBO where 550mg three times daily may be preferred by some specialists.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
RIFATUF 550 serves the specific hepatic encephalopathy indication where the 400mg dose is not the guideline standard. For hepatologists managing cirrhotic patients — a large and growing population in India given the high burden of alcoholic liver disease and viral hepatitis — RIFATUF 550 is an essential chronic prescription medication. RIFATUF 400 and 550 together provide Seclis Labs with complete rifaximin coverage across all gastroenterology and hepatology indications.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.